CD24: A Novel Target for Cancer Immunotherapy

Overview

Journal J Pers Med

Date 2022 Aug 26

PMID 36013184

Authors

Emmanouil Panagiotou

Nikolaos K Syrigos

Andriani Charpidou

Elias Kotteas

Ioannis A Vathiotis

Affiliations

Soon will be listed here.

Abstract

Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Siglec-10 interaction has been implicated in tumor immune evasion, inhibiting macrophage-mediated phagocytosis as well as natural killer (NK) cell cytotoxicity. CD24 blockade has shown promising results in preclinical studies. Although there are limited data on efficacy, monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in two clinical trials. Other treatment modalities evaluated in the preclinical setting include antibody-drug conjugates and chimeric antigen receptor (CAR) T cell therapy. In this review, we summarize current evidence and future perspectives on CD24 as a potential target for cancer immunotherapy.

Citing Articles

The Immunoexpression and Prognostic Significance of Stem Cell Markers in Malignant Salivary Gland Tumors: A Systematic Review and Meta-Analysis.

Kalogirou E, Tosiou A, Vrachnos S, Zogopoulos V, Michalopoulos I, Tzanavari T Genes (Basel). 2025; 16(1).

PMID: 39858584 PMC: 11764928. DOI: 10.3390/genes16010037.

MicroRNA Profiling of PRELI-Modulated Exosomes and Effects on Hepatic Cancer Stem Cells.

Kim B Int J Mol Sci. 2025; 25(24.

PMID: 39769068 PMC: 11678812. DOI: 10.3390/ijms252413299.

miR-210 Mediated Hypoxic Responses in Pancreatic Ductal Adenocarcinoma.

Mortoglou M, Lian M, Miralles F, Dart D, Uysal-Onganer P ACS Omega. 2024; 9(48):47872-47883.

PMID: 39651070 PMC: 11618397. DOI: 10.1021/acsomega.4c08947.

Cheminformatic Identification of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors: A Comparative Study of SMILES-Based Supervised Machine Learning Models.

Lai C, Kwok A, Wong K J Pers Med. 2024; 14(9).

PMID: 39338235 PMC: 11433629. DOI: 10.3390/jpm14090981.

Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms.

Han H, He T, Wu Y, He T, Zhou W Front Cell Dev Biol. 2024; 12:1441081.

PMID: 39184916 PMC: 11341543. DOI: 10.3389/fcell.2024.1441081.

References

Myung J, Gajjar K, Pearson R, Launiere C, Eddington D, Hong S . Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin. Anal Chem. 2011; 83(3):1078-83. PMC: 3059340. DOI: 10.1021/ac102901e. View

Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M . CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006; 131(2):630-9. DOI: 10.1053/j.gastro.2006.04.028. View

Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S . CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduct Target Ther. 2022; 7(1):224. PMC: 9283527. DOI: 10.1038/s41392-022-01030-x. View

Salnikov A, Bretz N, Perne C, Hazin J, Keller S, Fogel M . Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer. 2013; 108(7):1449-59. PMC: 3629417. DOI: 10.1038/bjc.2013.102. View

Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y . Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci. 2010; 57(2):165-75. View

Wu H, Liu J, Wang Z, Yuan W, Chen L . Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma. CNS Neurosci Ther. 2021; 27(10):1105-1117. PMC: 8446212. DOI: 10.1111/cns.13714. View

Gilliam D, Menon V, Bretz N, Pruszak J . The CD24 surface antigen in neural development and disease. Neurobiol Dis. 2016; 99:133-144. DOI: 10.1016/j.nbd.2016.12.011. View

Liu Y, Jones B, Aruffo A, Sullivan K, Linsley P, Janeway Jr C . Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med. 1992; 175(2):437-45. PMC: 2119117. DOI: 10.1084/jem.175.2.437. View

Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H . CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 2009; 101(1):112-9. PMC: 11159715. DOI: 10.1111/j.1349-7006.2009.01370.x. View

10.

Meng E, Long B, Sullivan P, McClellan S, Finan M, Reed E . CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 2012; 29(8):939-48. DOI: 10.1007/s10585-012-9482-4. View

11.

Sagiv E, Kazanov D, Arber N . CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother. 2006; 60(6):280-4. DOI: 10.1016/j.biopha.2006.06.006. View

12.

Uckun F, Song C . Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood. 1993; 81(5):1323-32. View

13.

Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X . Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Cancer Res. 2019; 79(13):3395-3405. DOI: 10.1158/0008-5472.CAN-18-2839. View

14.

Sun J, Feng D, Xi H, Luo J, Zhou Z, Liu Q . CD24 blunts the sensitivity of retinoblastoma to vincristine by modulating autophagy. Mol Oncol. 2020; 14(8):1740-1759. PMC: 7400807. DOI: 10.1002/1878-0261.12708. View

15.

Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

16.

Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri Y, Fujimoto J . CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. 2001; 166(9):5567-77. DOI: 10.4049/jimmunol.166.9.5567. View

17.

Xu K, Meng Z, Mu X, Sun B, Chai Y . One Single Site Clinical Study: To Evaluate the Safety and Efficacy of Immunotherapy With Autologous Dendritic Cells, Cytokine-Induced Killer Cells in Primary Hepatocellular Carcinoma Patients. Front Oncol. 2020; 10:581270. PMC: 7724106. DOI: 10.3389/fonc.2020.581270. View

18.

Lu S, Yao Y, Xu G, Zhou C, Zhang Y, Sun J . CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma. Cell Death Dis. 2018; 9(6):646. PMC: 5974417. DOI: 10.1038/s41419-018-0681-z. View

19.

Modur V, Joshi P, Nie D, Robbins K, Khan A, Rao K . CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma. PLoS One. 2016; 11(6):e0156651. PMC: 4898769. DOI: 10.1371/journal.pone.0156651. View

20.

Even-Zohar N, Pick M, Hofstetter L, Shaulov A, Nachmias B, Lebel E . CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. J Clin Med. 2022; 11(10). PMC: 9144978. DOI: 10.3390/jcm11102913. View